K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.

Acta Neuropathol 2012 Sep 3;124(3):439-47. Epub 2012 Jun 3.

Department of Human Genetics, McGill University, Montreal, QC, Canada.

Pediatric glioblastomas (GBM) including diffuse intrinsic pontine gliomas (DIPG) are devastating brain tumors with no effective therapy. Here, we investigated clinical and biological impacts of histone H3.3 mutations. Forty-two DIPGs were tested for H3.3 mutations. Wild-type versus mutated (K27M-H3.3) subgroups were compared for HIST1H3B, IDH, ATRX and TP53 mutations, copy number alterations and clinical outcome. K27M-H3.3 occurred in 71 %, TP53 mutations in 77 % and ATRX mutations in 9 % of DIPGs. ATRX mutations were more frequent in older children (p < 0.0001). No G34V/R-H3.3, IDH1/2 or H3.1 mutations were identified. K27M-H3.3 DIPGs showed specific copy number changes, including all gains/amplifications of PDGFRA and MYC/PVT1 loci. Notably, all long-term survivors were H3.3 wild type and this group of patients had better overall survival. K27M-H3.3 mutation defines clinically and biologically distinct subgroups and is prevalent in DIPG, which will impact future therapeutic trial design. K27M- and G34V-H3.3 have location-based incidence (brainstem/cortex) and potentially play distinct roles in pediatric GBM pathogenesis. K27M-H3.3 is universally associated with short survival in DIPG, while patients wild-type for H3.3 show improved survival. Based on prognostic and therapeutic implications, our findings argue for H3.3-mutation testing at diagnosis, which should be rapidly integrated into the clinical decision-making algorithm, particularly in atypical DIPG.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00401-012-0998-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422615PMC
September 2012
154 Reads

Publication Analysis

Top Keywords

copy number
8
biologically distinct
8
clinically biologically
8
distinct subgroups
8
tp53 mutations
8
h33 mutations
8
intrinsic pontine
8
diffuse intrinsic
8
defines clinically
8
pontine gliomas
8
atrx mutations
8
histone h33
8
mutations
7
h33
5
k27m-h33
5
type group
4
h33 wild
4
wild type
4
long-term survivors
4
notably long-term
4

References

(Supplied by CrossRef)

U Bartels et al.
J Neurooncol 2011

BE Bernstein et al.
Cell 2006

E Bouffet et al.
Cancer Treat Rev 2010

A Broniscer et al.
J Clin Oncol 2007

C Bueno et al.
Leukemia 2011

L Carramusa et al.
J Cell Physiol 2007

A Dhayalan et al.
Hum Mol Genet 2011

PG Fisher et al.
Pediatr Blood Cancer 2008

CR Freeman et al.
Childs Nerv Syst 1999

A Gajjar et al.
J Clin Oncol 1997

MH Jansen et al.
Cancer Treat Rev 2012

Similar Publications